
AMRI Awarded API Contract
AMRI has been awarded a seven-year contract for an active ingredient under clinical evaluation.
AMRI will initially work on the development and scale-up of the investigational drug, and the manufacture and supply for use during Phase I clinical trials. If the trials are successful, AMRI could become the commercial manufacturer of the product for distribution to the government partners of this contract, including the UK, the Netherlands, and Canada.
Source:
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





